Drug Trial Radar · NCT06537817
Study to Evaluate HT-4253 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Sep 17, 2024
Primary completion
May 12, 2025
Study completion May 12, 2025
Sponsor
- Lead sponsor
- Halia Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects. The secondary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of HT-4253.
Conditions
- Normal Healthy Subjects
Interventions
HT-4253Drug
HT-4253 Single or Multiple doses administered orally as a tablet
PlaceboDrug
Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
- To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
- To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
- To evaluate the safety and tolerability of single and multiple ascendingTime frame: up to 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.